“…In the last 2 decades, different molecules have been designed as CORMs, particularly transitional metal carbonyl complexes, which contain a heavy metal surrounded by carbonyl (CO) groups as the coordinated ligand . A great variety of metals have been tested, including ruthenium, molybdenum, and iridium. − However, nonmetal-based CORMs have also been developed . Both metal and nonmetal-based CORMs possess alternative trigger mechanisms responsible for the CO release. , The design of CORMs that is able to release the CO site specifically has been a big challenge since their inception: the first CORMs were hardly water soluble, and the release of CO was too fast. , Soon after, Motterlini and co-workers developed the water-soluble metal complex tricarbonylchloro(glycinato)ruthenium(II) (CORM-3), which exhibits an anti-inflammatory action in vivo as well as renoprotective and antiapoptotic effects. − However, despite the potential beneficial effects, the clinical application of CORM-3 is limited due to the lack of suitable drug-like properties, namely, its reduced CO release half-time and poor stability in aqueous media …”